IMR Press / FBL / Volume 27 / Issue 1 / DOI: 10.31083/j.fbl2701019
Open Access Communication
Modification Tadalafil and Macitentan tablets to aerosol
Show Less
1 Pulmonary Department, “Bioclinic” Private Hospital, 115 24 Thessaloniki, Greece
2 3rd University General Hospital, “AHEPA” University Hospital, 546 21 Thessaloniki, Greece
3 Department of Food Technology, School of Food Technology and Nutrition, Alexander Technological Educational Institute, 574 00 Thessaloniki, Greece
4 Department of Pharmacology & Clinical Pharmacology, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, 541 24 Thessaloniki, Greece
5 Thoracic Surgery Department, “Interbalkan” European Medical Center, 555 35 Thessaloniki, Greece
6 Oncology Department, General Hospital of Rhodos, 851 33 Rhodos, Greece
7 Department of Respiratory & Critical Care Medicine, Changhai Hospital, The Second Military Medical University, 200433 Shanghai, China
8 Sana Clinic Group Franken, Department of Cardiology/Pulmonology/Intensive Care/Nephrology, “Hof’’ Clinics, University of Erlangen, 91054 Hof, Germany
9 Pulmonary Department, “G. Papanikolaou” General Hospital, Aristotle University of Thessaloniki, 541 24 Thessaloniki, Greece
10 First Department of Cardiology, AHEPA University Hospital, Aristotle University of Thessaloniki, 541 24 Thessaloniki, Thessaloniki, Greece
11 Department of Pulmonology, I.M. Sechenov First Moscow State Medical University, 119435 Moscow, Russian Federation
12 Ear, Nose and Throat (ENT) Department, Ludwig-Maximilians University of Munich, 80539 Munich, Germany

Academic Editor: Josef Jampílek

Front. Biosci. (Landmark Ed) 2022, 27(1), 19;
Submitted: 29 November 2021 | Revised: 12 December 2021 | Accepted: 22 December 2021 | Published: 13 January 2022
Copyright: © 2022 The Author(s). Published by IMR Press.
This is an open access article under the CC BY 4.0 license.

Introduction: Aerosolised drugs have been approved for several diseases such as cystic fibrosis and diabetes. Moreover; there are already drugs for pulmonary hypertension in aerosol form already on the market. Materials and methods: Two drugs for pulmonary hypertension (Tadalafil and Macitentan) were milled and transformed from tablets to powder. Three different jet-nebulizers with seven different residual cups were combined. Moreover, we used 3 different ultrasound nebulizers with two different release methods. Results: The drug and residual cup designs produce alone or jointly different MMAD diameters. The three large (10 mls) residual cups with the jet-nebulisers produced the smallest aerosol droplets. Both ultrasound nebulisers are capable of producing optimal size aerosol droplets 5 μm mmad. Conclusions: These two drugs can be easily administered as aerosol and an vivo clinical study will prove the safety for the airways.

Ultrasound nebulizers
Pulmonary hypertension
Fig. 1.
Back to top